Skip to main content
SpringerLink
Log in

Adalimumab

Lack of efficacy due to development of antibodies to adalimumab: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nita AF, et al. Satisfactory switch to Infliximab after adalimumab loss of response in a teenager with severe Crohn's disease. European Journal of Pediatrics 178 (Suppl.): 1668 abstr. 457, No. 11, 2019. Available from: URL: http://doi.org/10.1007/s00431-019-03466-w [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab. Reactions Weekly 1823, 20 (2020). https://doi.org/10.1007/s40278-020-83648-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-83648-9

Search

Navigation